Hypomagnesemia 4, Renal
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.
|
17671655 |
2007 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in the epidermal growth factor gene receptor (EGFR) occur predominantly in non-smokers with adenocarcinoma.
|
28144970 |
2017 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We analyzed exons 19 and 21 coding for the receptor tyrosine kinase of the epidermal growth factor gene in 105 samples of esophageal (Barrett's) adenocarcinoma by denaturing high-pressure liquid chromatography.
|
17227303 |
2007 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Clinical predictors including Asian, female, adenocarcinoma and never-smoker and epidermal growth factor mutation are associated with gefitinib responsiveness in non-small-cell lung cancer.
|
16956694 |
2006 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome.
|
18483390 |
2008 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Southern blot analysis of DNAs isolated from 25 ovarian adenocarcinomas revealed no amplification of the IGF-I-R or the EGF-R gene.
|
1325950 |
1992 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition, the <i>epidermal growth factor receptor</i> mutation rate was higher in the adenocarcinoma histologic type (p<0.001).
|
28832323 |
2017 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population.
|
26625757 |
2015 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
EGF specific binding sites were detected in about 50% of adenocarcinomas (ovarian, endometrial, breast) and in over 90% of squamous carcinomas (cervical).
|
2285597 |
1990 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Polymerase chain reaction restriction fragment length polymorphism analyses were used to genotype EGF +61 in 207 patients with gastric lesions (162 patients with gastric adenocarcinomas, 45 with atrophy or intestinal metaplasia) and 984 controls.All subjects were Caucasian.
|
21274378 |
2011 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Previous studies have shown a correlation between expression of the EGF receptor type III mutation (EGFRvIII) and a more malignant phenotype of various cancers including: non-small-cell lung cancer, glioblastoma multiforme, prostate cancer and breast cancer.
|
11710837 |
2001 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results do not support a strong association between common variants in the ESR1 and EGF genes and breast cancer risk, tumour characteristics or survival.
|
18271972 |
2008 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Further, we showed that the waiting time for onset of breast cancer in G homozygous patients for EGF genotypes (55 years) was significantly lower in comparison to A-allele carriers (59 years) (log-rank test: p = 0.038).
|
19388850 |
2009 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Trastuzumab (Herceptin) is the first monoclonal antibody to be approved for the treatment of a solid tumour and is directed against the c-erb-B2 receptor. c-erb-B2 is a member of the epidermal growth factor family and approximately 25% of breast cancers express such receptors, which appear to confer a poorer prognosis and may be an indicator of resistance to cytotoxic chemotherapy.
|
11824879 |
2001 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The existence of such field within the human breast was inferred from the results on primary breast cancer obtained by PCR-based microsatellite analysis of allelic imbalance (AI) of the EGF receptor gene.
|
18690849 |
2008 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Levels of breast cancer 1 (BRCA1), EGF receptor (EGFR, also known as ERBB1), ERBB4, tubulointerstitial nephritis antigen-like 1 (TINAGL1) and ESR1 protein were examined with immunohistochemical analysis using immunofluorescence methods and confocal laser scanning microscopy.
|
28810691 |
2017 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings indicated that plasma EGF levels served as a protective marker against breast cancer in our study and EGF G-1380A variant might be a modifier on it.
|
17940864 |
2008 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 (HER2 gene) and chromosome 17 polysomy are associated with breast cancer prognosis, chemotherapy and hormone therapy.
|
25119636 |
2014 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
|
11454673 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma.
|
17175377 |
2007 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas.
|
9334810 |
1997 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found 7 SNPs in haplotype 4 in EGF that were associated with prognosis in glioblastoma patients.
|
20197289 |
2010 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas.
|
11087732 |
2001 |
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
|
15700833 |
2004 |